Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 6, 2004, Pages 601-608

  Ganaha, Fumikiyo ^a   Kao, Edward Y ^a   Wong, Humberto ^a   Elkins, Christopher J ^a   Lee, Jane ^a   Modanlou, Shoreh ^a   Rhee, Ceron ^a   Kuo, Michael D ^a   Yuksel, Eser ^b   Cifra, Pamela N ^a   Waugh, Jacob M ^a   Dake, Michael D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; MICROSPHERE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CELL PROLIFERATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE COURSE; DRUG ELUTING STENT; EVALUATION; HEART MUSCLE REVASCULARIZATION; INFLAMMATION; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSTHESIS MATERIAL; RABBIT; RESTENOSIS; STATISTICAL SIGNIFICANCE; STENT; VASCULAR SMOOTH MUSCLE;

EID: 2942620071     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000127888.70058.93     Document Type: Article

References (43)

1. Jacobs AK. Coronary stents-have they fulfilled their promise? N Engl J Med 1999; 341:2005-2006.
2. Bauters C, Banos JL, Van Belle E, Fadden EP, Lablanche JM, Bertrand ME. Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation 1998; 97:318-321.
3. Yutani C, Imakita M, Ishibashi-Ueda H, Tsukamoto Y, Nishida N, Ikeda Y. Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol Int 1999; 49:273-290.
4. Reimers B, Moussa I, Akiyama T, et al. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. J Am Coll Cardiol 1997; 30:186-192.
5. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57:791-804.
6. Libby P, Tanaka H. The molecular bases of restenosis. Prog Cardiovasc Dis 1997; 40:97-106.
7. Mintz GS, Popma JJ, Pichard AD, et al. Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J Am Coll Cardiol 1996; 27:1678-1687.
8. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circulation Res 1995; 76:996-1002.
9. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol. 1998; 81:14E-17E.
10. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94:1247-1254.
11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
12. Marks AR. Sirolimus for the prevention of in-stent restenosis in a corornary artery. N Engl J Med 2003; 349: 1307-1309.
13. Marx SO, Marks AR. Bench to bed-side: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104:852-855.
14. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
15. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99:1726-1732.
16. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7:425-429.
17. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8:403-409.
18. Elkins CJ, Waugh JM, Amabile PG, et al. Development of a Platform to Evaluate and Limit In-Stent Restenosis. Tissue Eng 2002; 8:395-407.
19. Yuksel E, Weinfeld AB, Cleek R, et al. De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: a novel concept and capability. Plat Reconstr Surg 2000; 105:1721-1729.
20. Wong AH, Waugh JM, Amabile PG, Yuksel E, Dake MD. In vivo vascular engineering: directed migration of smooth muscle cells to limit neointima. Tissue Eng 2002; 8:189-199.
21. Wong AH, Amabile PG, Yuksel E, Waugh JM, Dake MD. Perivascular release of insulin-like growth factor-1 limits neointima formation in the balloon-injured artery by redirecting smooth muscle cell migration. J Vasc Interv Radiol 2001; 12(3):347-350.
22. Yuksel E, Weinfeld AB, Cleek R, et al. Increased free fat-graft survival with the long-term, local delivery of insulin, insulin-like growth factor-I, and basic fibroblast growth factor by PLGA/PEG microspheres. Plat Reconstr Surg 2000; 105:1712-1720.
23. Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide- co- glycolide). Nat Biotechnol 2000; 18:52-57.
24. Celletti FL, Waugh JM, Amabile PG, Kao EY, Boroumand S, Dake MD. Inhibition of vascular endothelial growth factor-mediated neointima progression with angiostatin or paclitaxel. J Vasc Interv Radiol 2002; 13:703-707.
25. Waugh JM, Li-Hawkins J, Yuksel E, et al. Thrombomodulin overexpression to limit neointima formation. Circulation 2000; 102:332-337.
26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
27. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
28. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-153.
29. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
30. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999; 274: 29568-29571.
31. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2:689-692.
32. Sim BK, O'Reilly MS, Liang H, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329-1334.
33. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997; 272:28823-28825.
34. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. N Engl J Med 1994; 331:1729-1734.
35. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001; 37:2126-2130.
36. Katsuda S, Boyd HC, Fligner C, Ross R, Gown AM. Human atherosclerosis. III. Immunocytochemical analysis of the cell composition of lesions of young adults Am J Pathol 1992; 140:907-914.
37. Patterson JC. Capillary rupture with intimal hemorrhage as a causative factors in coronary thrombosis. Arch Pathol 1938; 25:474-487.
38. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998; 135:10-14.
39. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation. 1992; 86(6 suppl): III95-III99.
40. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87:3336-3343.
41. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172:1535-1545.
42. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-1312.
43. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro. Arterioscler Thromb Vasc Biol 1999; 19: 2041-2048.